Clinical trials: Recurrent Prostate Adenocarcinoma
Prostate Cancer
Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide and bicalutamide, may lessen the amount of androgens made by the body.
- Trial name
- NCT00684905
- Testing
- bicalutamide, leuprolide acetate, adjuvant therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Prostate Cancer
APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
Phase II trial to study the effectiveness of APC8015 combined with bevacizumab in treating patients who have undergone radiation therapy and/or surgery and who have progressive prostate cancer.
- Trial name
- NCT00027599
- Testing
- bevacizumab, prostatic acid phosphatase-sargramostim fusion protein, sipuleucel-T
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells.
- Trial name
- NCT00002855
- Testing
- Bicalutamide, Doxorubicin hydrochloride, Estramustine Phosphate Sodium
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- M.D. Anderson Cancer Center
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial
This phase II trial evaluates an imaging technique (rhPSMA-7.3 positron emission tomography [PET]/computed tomography [CT]) for detecting prostate cancer in patients who have increasing prostate-specific antigen levels following…
- Trial name
- NCT06813898
- Testing
- Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Northwestern University
Prostate Cancer
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens.
- Trial name
- NCT00110162
- Testing
- antiandrogen therapy, releasing hormone agonist therapy, orchiectomy
- Where
- 20 sites in Australia, New Zealand
- Volunteers
- 2,000 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostate Cancer
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for the treatment of men with prostate cancer who are starting long-term ADT for the first time, termed hormone-naïve prostate cancer.
- Trial name
- STAMPEDE (NCT00268476)
- Testing
- Celecoxib, Docetaxel, Prednisolone
- Where
- 120 sites in Switzerland, United Kingdom
- Volunteers
- 11,992 people
- Sponsor
- Medical Research Council
Prostate Cancer
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
RATIONALE: Gene mutations may make prostate cancer cells unable to attach to androgens. This may permit the growth of prostate cancer. Gene testing may improve the identification of patients with advanced prostate cancer.
- Trial name
- NCT00002924
- Testing
- mutation analysis
- Where
- 49 sites in United States
- Volunteers
- 184 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003653
- Testing
- bicalutamide, buserelin, cyproterone acetate
- Where
- 29 sites in Canada
- Volunteers
- 1,386 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer
BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have prostate…
- Trial name
- NCT00016393
- Testing
- ixabepilone
- Where
- 28 sites in United States
- Sponsor
- SWOG Cancer Research Network
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
This phase I trial is studying the side effects and best dose of temsirolimus when given together with hormone therapy in treating patients with relapsed prostate cancer. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00512668
- Testing
- leuprolide acetate, goserelin acetate, bicalutamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Cancer, Prostate Cancer
Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00080678
- Testing
- Docetaxel, Imatinib Mesylate
- Where
- 3 sites in United States
- Volunteers
- 116 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy
RATIONALE: White button mushroom extract may stop or delay the development of recurrent prostate cancer. PURPOSE: This phase I trial is studying the side effects and best dose of white button mushroom extract in treating patients…
- Trial name
- NCT00779168
- Testing
- white button mushroom extract, flow cytometry, immunologic technique
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide
This research trial studies molecular features and pathways in predicting drug resistance in patients with castration-resistant prostate cancer that has spread to other parts of the body and who are receiving enzalutamide.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, PSA Progression
- Trial name
- NCT02228265
- Testing
- Cytology Specimen Collection Procedure, Enzalutamide, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer, Sexual Dysfunction and Infertility
Hormone Therapy in Treating Patients With Prostate Cancer
RATIONALE: Male hormones can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide and finasteride may fight prostate cancer by reducing the production of male hormones.
- Trial name
- NCT00003323
- Testing
- finasteride, flutamide, quality-of-life assessment
- Where
- 43 sites in United States
- Volunteers
- 101 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer (Adenocarcinoma)
Predictive Factors for 10-year Biochemical Recurrence and Urinary Continence Following Robot-assisted Radical Prostatectomy for Prostate Cancer
The aim of the present project is to evaluate long-term oncological and functional treatment outcomes, as well as patient satisfaction, ten years after radical prostatectomy in patients initially enrolled in CPRRP study.
- Trial name
- NCT07439913
- Testing
- Radical prostatectomy
- Where
- Slovakia
- Volunteers
- 120 people
- Sponsor
- F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
Prostate Cancer
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating men who have stage IV…
- Trial name
- NCT00005820
- Testing
- nitrocamptothecin
- Where
- 50 sites in United States
- Volunteers
- 35 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than once drug may kill more tumor cells.
- Trial name
- NCT00003717
- Testing
- estramustine phosphate sodium, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- St. Barnabas Medical Center
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer
Phase II trial to study the effectiveness of combination chemotherapy plus monoclonal antibody therapy in treating patients who have metastatic prostate cancer that has not responded to previous hormone therapy.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00016107
- Testing
- estramustine phosphate sodium, docetaxel, bevacizumab
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of prostate cancer.
- Trial name
- NCT00025116
- Testing
- gefitinib
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group